Dillard's, Inc. will announce its financial results for the third quarter and the first 39 weeks of 2026 on November 12, before the Texas Stock Exchange opens. This report will provide investors with updated insights into the company's recent performance and financial health. The announcement is important for shareholders and market watchers to assess Dillard's business trends and outlook for the remainder of the year.
Dillard’s, Inc. is set to report its third quarter and year-to-date results on November 12. For readers following the Consumer Cyclical sector, here is Pluang's market snapshot as of Nov 12, 2026 03:51 WIB: Out of 134 priced US stocks, 51 rose and 81 fell. Notable movers include Dana Incorporated Common Stock (DAN) at USD 23.19 with a 1-day change of -2.93%, Lucid Group Inc (LCID) at USD 3.66 down 2.92% with a typical hold time of 46 days and a nearly balanced Pluang order activity of 49% Sell / 51% Buy, and Capri Holdings Ltd (CPRI) at USD 21.11 down 2.85% with 100% sell orders.
Ashland Inc.'s board of directors declared a quarterly cash dividend of $0.42 per share, payable on December 15, 2026, to shareholders of record as of December 1, 2026. This dividend reflects the company's ongoing commitment to returning value to sha...
AeroVironment secured a $405 million international order for its LOCUST X3 high-energy laser weapon systems, enhancing counter-drone defense capabilities in the Middle East amid rising regional security threats. Following the announcement, AeroVironm...
Vestas Wind Systems reported Q3 2026 earnings per share of $0.13 and revenue of $6.34 billion, both below analyst expectations. The company's profit was impacted by weak sales volume and a broken turbine blade. Following the earnings miss, Vestas' sh...
The global beverage market is projected to grow from $2.03 trillion in 2026 to $2.78 trillion by 2032, at a CAGR of 5.35%. Growth is fueled by rising demand for nonalcoholic and functional beverages, convenience packaging, and premium products for sp...
DelveInsight's 2026 report reveals more than 200 GLP-1 receptor agonists and incretin-based therapies are in development by over 180 companies, targeting conditions like type 2 diabetes, obesity, and related metabolic disorders. Key players such as E...
